CN119700968A - 用于治疗克罗恩氏病的方法中的米吉珠单抗 - Google Patents

用于治疗克罗恩氏病的方法中的米吉珠单抗 Download PDF

Info

Publication number
CN119700968A
CN119700968A CN202411949868.6A CN202411949868A CN119700968A CN 119700968 A CN119700968 A CN 119700968A CN 202411949868 A CN202411949868 A CN 202411949868A CN 119700968 A CN119700968 A CN 119700968A
Authority
CN
China
Prior art keywords
jizhu
mab
weeks
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411949868.6A
Other languages
English (en)
Chinese (zh)
Inventor
S·W·弗里德里希
P·F·波拉克
J·L·塔特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN119700968A publication Critical patent/CN119700968A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
CN202411949868.6A 2019-04-22 2020-04-15 用于治疗克罗恩氏病的方法中的米吉珠单抗 Pending CN119700968A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962836910P 2019-04-22 2019-04-22
US62/836910 2019-04-22
PCT/US2020/028273 WO2020219314A1 (en) 2019-04-22 2020-04-15 Mirikizumab for use in a method of treating crohn's disease
CN202080030747.5A CN113677366A (zh) 2019-04-22 2020-04-15 用于治疗克罗恩氏病的方法中的米吉珠单抗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080030747.5A Division CN113677366A (zh) 2019-04-22 2020-04-15 用于治疗克罗恩氏病的方法中的米吉珠单抗

Publications (1)

Publication Number Publication Date
CN119700968A true CN119700968A (zh) 2025-03-28

Family

ID=70554215

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411949868.6A Pending CN119700968A (zh) 2019-04-22 2020-04-15 用于治疗克罗恩氏病的方法中的米吉珠单抗
CN202080030747.5A Pending CN113677366A (zh) 2019-04-22 2020-04-15 用于治疗克罗恩氏病的方法中的米吉珠单抗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080030747.5A Pending CN113677366A (zh) 2019-04-22 2020-04-15 用于治疗克罗恩氏病的方法中的米吉珠单抗

Country Status (17)

Country Link
US (1) US20220040299A1 (enExample)
EP (1) EP3958897A1 (enExample)
JP (3) JP7297930B2 (enExample)
KR (2) KR20250153865A (enExample)
CN (2) CN119700968A (enExample)
AU (2) AU2020263238C1 (enExample)
BR (1) BR112021018930A2 (enExample)
CA (1) CA3134587A1 (enExample)
EA (1) EA202192532A1 (enExample)
IL (2) IL286818B1 (enExample)
MA (1) MA55756A (enExample)
MX (1) MX2021012848A (enExample)
SG (1) SG11202110619XA (enExample)
TW (2) TWI850365B (enExample)
UA (1) UA128657C2 (enExample)
WO (1) WO2020219314A1 (enExample)
ZA (1) ZA202108094B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
KR20220066831A (ko) 2020-11-16 2022-05-24 엔브이에이치코리아(주) 습기경화형 접착제를 이용한 헤드라이닝 제조방법 및 이에 의해 제조되는 헤드라이닝

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
EP3693007A1 (en) 2013-03-15 2020-08-12 Amgen, Inc Methods for treating crohn's disease using an anti-il23 antibody
TWI811716B (zh) * 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
AU2017312049A1 (en) * 2016-08-19 2019-02-21 Janssen Biotech, Inc. Methods of treating Crohn's Disease with an anti-NKG2D antibody
KR20200037258A (ko) * 2017-07-10 2020-04-08 람밤 메드-테크 엘티디. 생물학적 약물로 치료받은 피험자에서 중화 항체 수준 평가용 분석법 및 맞춤 의료에서 이의 사용
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法

Also Published As

Publication number Publication date
JP2022530397A (ja) 2022-06-29
JP7761614B2 (ja) 2025-10-28
AU2020263238C1 (en) 2024-02-22
KR20210142704A (ko) 2021-11-25
AU2023265759A1 (en) 2023-12-07
TW202103734A (zh) 2021-02-01
US20220040299A1 (en) 2022-02-10
BR112021018930A2 (pt) 2022-01-18
CA3134587A1 (en) 2020-10-29
UA128657C2 (uk) 2024-09-18
IL324048A (en) 2025-12-01
CN113677366A (zh) 2021-11-19
EP3958897A1 (en) 2022-03-02
WO2020219314A1 (en) 2020-10-29
JP7297930B2 (ja) 2023-06-26
EA202192532A1 (ru) 2022-01-21
AU2020263238A1 (en) 2021-11-04
ZA202108094B (en) 2025-05-28
NZ781127A (en) 2025-06-27
IL286818A (en) 2021-10-31
AU2020263238B2 (en) 2023-08-17
SG11202110619XA (en) 2021-11-29
TWI850365B (zh) 2024-08-01
JP2023116680A (ja) 2023-08-22
IL286818B1 (en) 2025-11-01
JP2025148449A (ja) 2025-10-07
MX2021012848A (es) 2021-12-10
KR102869852B1 (ko) 2025-10-14
KR20250153865A (ko) 2025-10-27
TW202515610A (zh) 2025-04-16
MA55756A (fr) 2022-03-02

Similar Documents

Publication Publication Date Title
US20250034243A1 (en) Methods of treating ulcerative colitis
JP2025148449A (ja) クローン病を治療する方法に使用するためのミリキズマブ
EA045979B1 (ru) Мирикизумаб для применения в способе лечения болезни крона
HK40036550A (en) Mirikizumab in the treatment of ulcerative colitis
HK40036550B (en) Mirikizumab in the treatment of ulcerative colitis
HK40101440A (en) Mirikizumab in the treatment of ulcerative colitis
EA049081B1 (ru) Способы лечения язвенного колита

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination